FindTrial
Sign In

Applications of HE 4 in fibrotic diseases

Application of HE4 in connective tissue-associated pulmonary fibrosis disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029039
Enrollment
Unknown
Registered
2020-01-12
Start date
2020-01-07
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibrotic Disease

Interventions

Fibrotic patients:Nil

Sponsors

Shanxi dayi Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient group: 1. Sign informed consent; 2. rheumatology and Immunology patients, respiratory patients, cardiology patients, dermatology and radiotherapy patients. Control group 1. Population with good physical examination results 2. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Researcher considers to stop the trial from the perspective of medicine; 2. the patient requires to stop the participate.

Design outcomes

Primary

MeasureTime frame
HE4;—

Countries

China

Contacts

Public ContactZhang Mingxia

Shanxi Dayi Hospital

sxdyy8358@126.com+86 0351 8368562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026